is Director of IRM Program in Musculoskeletal Regeneration and Associate Professor of Orthopaedic Surgery and Bioengineering. Dr. Mauck is an expert in the development of tissue-engineered biologic replacements for a range of musculoskeletal tissues. He and his collaborators have demonstrated that both mechanical signals and sophisticated biomaterial design can be integrated to direct the formation of functional new tissues using adult progenitor cells.
is Co-Director of the IRM Program in Musculoskeletal Regeneration and Professor of Bioengineering. His research interests include developing degradable polymeric biomaterials that can be used for tissue engineering, drug delivery, and fundamental polymer studies.
is Co-Director of the IRM Program in Musculoskeletal Regeneration and Assistant Professor of Orthopaedic Surgery and Cell and Developmental Biology. Dr. Mourkioti has recently developed a new mouse model that mimics more faithfully Duchenne Muscular Dystrophy, providing novel evidence that the skeletal muscle phenotype is caused by a failure of skeletal muscle stem cells to maintain the damage-repair cycle initiated by dystrophin deficiency. This model is also the first mouse with a spontaneous cardiac phenotype, including dilated cardiomyopathy, cardiac dysfunction and arrhythmias and increased vulnerability to stress, features typically seen in DMD patients. Her laboratory is focused on combining genetic knockout mice and gene recombination with cellular engineering techniques to investigate the temporal and spatial communication of cells and signaling pathways during muscle regeneration.
This program seeks to address the degeneration of the musculoskeletal system by bringing together innovative scientists, clinicians, and engineers to develop novel regenerative medicine treatments for the repair and replacement of musculoskeletal tissues. The Program in Musculoskeletal Regeneration is nationally recognized for contributions to the development of new biomaterials used to repair musculoskeletal tissues (including cartilage, bone, disc, and tendons and ligaments), the use of adult and other progenitor cells in the development of tissue engineered constructs for musculoskeletal applications and forwarding our understanding of how musculoskeletal tissues form during development and repair after injury.
- Developed novel biomaterials that can direct new tissue formation for the repair of dense connective tissues like the knee meniscus and the intervertebral disc (Baker, et al.: PNAS, 2012, Nerurkar, et al.: Nat. Materials, 2009).
- Discovered novel roles for retinoic acid agonists in regulating bone formation in vivo (Shimono, et al.: Nat. Medicine, 2011).
- Identified new molecular pathways essential for bone formation and regeneration (Shitaye, et al.: Matrix Biol., 2010, Zhu, et al.: J. Cell. Physiol., 2012, Dishowitz, et al.: J. Orthop. Res., 2012).
- Identified novel progenitor cell populations in developing limbs that contribute to joint tissue formation and repair (Mundy, et al.: Dev. Bio, 2011).
- Produced engineered articular cartilage replacement materials with native-like tissue properties using custom 3d hydrogels and adult stem cell populations (Erickson, et al.: Acta Biomat., 2012, Kim, et al.: Biomat., 2011, Bian, et al.: Biomat., 2011).
- The development of novel translational models in which to test the efficacy of new musculoskeletal regenerative medicine therapies.
- The clinical translation of these novel regenerative medicine approaches to cure musculoskeletal injury in patients of all ages.